Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Arcturus Therapeutics is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 177 staff and has a trailing 12-month revenue of around $51.5 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $21.24 |
|---|---|
| 52-week range | $11.70 - $31.41 |
| 50-day moving average | $17.97 |
| 200-day moving average | $17.54 |
| Wall St. target price | $43.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-7.53 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $21.24 from 2023-02-06
| 1 week (2023-01-31) | 0.52% |
|---|---|
| 1 month (2023-01-06) | 29.43% |
| 3 months (2022-11-08) | -6.92% |
| 6 months (2022-08-08) | 1.05% |
| 1 year (2022-02-08) | -15.31% |
|---|---|
| 2 years (2021-02-08) | -75.56% |
| 3 years (2020-02-07) | 76.56% |
| 5 years (2018-02-07) | 231.88% |
| Revenue TTM | $51.5 million |
|---|---|
| Gross profit TTM | $12.4 million |
| Return on assets TTM | -25.22% |
| Return on equity TTM | -72.46% |
| Profit margin | -284.78% |
| Book value | $5.50 |
| Market capitalisation | $585.3 million |
TTM: trailing 12 months
We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.
Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.
Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $11.7 up to $31.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.5563. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U. S.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.